Riverview Trust Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Riverview Trust Company’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24.6K	Hold	55	–	–	0.03%	139
2025 Q4	$24.9K	Hold	55	–	–	0.03%	151
2025 Q3	$21.5K	Hold	55	–	–	0.03%	160
2025 Q2	$24.5K	Sell	55 -194	-78%	-$89.4K	0.03%	162
2025 Q1	$121K	Sell	249 -6	-2%	-$2.8K	0.12%	137
2024 Q4	$103K	Buy	255 +1	+0.4%	+$464	0.09%	154
2024 Q3	$118K	Buy	254 +60	+31%	+$28.8K	0.1%	151
2024 Q2	$90.9K	Hold	194	–	–	0.09%	165
2024 Q1	$81.1K	Buy	+194	New	+$82K	0.06%	185
2023 Q4	–	Sell	-194	Closed	-$67.5K	–	622
2023 Q3	$67.5K	Hold	194	–	–	0.06%	198
2023 Q2	$68.3K	Hold	194	–	–	0.06%	169
2023 Q1	$61.1K	Hold	194	–	–	0.06%	182
2022 Q4	$56K	Hold	194	–	–	0.05%	200
2022 Q3	$56K	Hold	194	–	–	0.05%	188
2022 Q2	$55K	Hold	194	–	–	0.05%	201
2022 Q1	$51K	Buy	+194	New	+$46K	0.04%	222

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Riverview Trust Company's VRTX Position: Q1 2026 in Review

Riverview Trust Company held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 55 shares worth $24.6K. The position accounts for 0.03% of the portfolio, ranked #139.

Riverview Trust Company first reported a position in VRTX in Q1 2022 and has held it in 16 quarters since. The position peaked at $121K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Riverview Trust Company held 55 shares of Vertex Pharmaceuticals worth $24.6K as of Q1 2026.
Riverview Trust Company left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.03% of Riverview Trust Company's portfolio in Q1 2026, its #139 holding.
Riverview Trust Company first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
Riverview Trust Company's Vertex Pharmaceuticals position peaked at $121K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Riverview Trust Company's 13F filing for Q1 2026, filed 1 May 2026.